Novo Nordisk: Switch To Weekly Ozempic Has Begun, Biopharma M&A Sought
But elephant in the room – the coming stream of readouts from Phase III PIONEER trials on oral semaglutide in Type 2 diabetes – gets little mention at first-quarter update.
You may also be interested in...
In second Phase III diabetes study to report, oral GLP-1 agonist semaglutide misses some weight loss goals when compared with Boehringer/Lilly's SGLT-2 inhibitor Jardiance.
Denmark's diabetes specialty company has linked up with a US biotech to evaluate a lysophosphatidic acid receptor antagonist in diabetic and chronic kidney disease.
In PIONEER 1, weight loss results for the oral version of the GLP-1 agonist were somewhat disappointing and lack of detail in the top-line release prompts concerns about compliance.